FDA authorises restart of the COVID-19 AZD1222 vaccine US Phase III trial
AZD1222 clinical trials now resumed globallyClinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed across the world with regulators in the US, UK, Brazil, South Africa and Japan confirming that it was safe to do so. The Food and Drug Administration (FDA) today authorised the restart in the US, following the resumption of trials in other countries in recent weeks. The FDA reviewed all safety data from trials globally and concluded it was safe to resume the trial. As part of the standard review process for trial safety events, a voluntary pause to